Comparing Armistice Capital's Q3 2022 vs. Q4 2022 13F Holdings

2022 has been a year of uncertainty for the stock market. With the COVID-19 pandemic still raging around the world, it is no surprise that investors are cautious in their investments. In the midst of all this, Armistice Capital released its 2022 third-quarter 13F filings, which showed a mixed performance. However, by the end of the fourth quarter, we saw changes in positions that resulted in a significant gain of about 7.1%. In this blog post, we will take a closer look at Armistice Capital's Q3 2022 vs. Q4 2022 13F holdings comparison.

Armistice Capital, LLC is an investment management firm managing over $1.1 billion in assets. Founded in 2012, the company focuses on healthcare investments and has a value-driven, patient approach to investing. The firm invests primarily in small to mid-cap biotechnology, pharmaceuticals, and medical devices.

A 13F filing reports the holdings of institutional investors. These quarterly filings with the Securities and Exchange Commission (SEC) are necessary for any institutional investment managers with assets under management of more than $100 million. The SEC requires them to disclose their holdings of publically traded common stocks, options, and convertible debt securities. The Q3 13F filing showed that Armistice Capital had holdings in over 40 companies valued at around $1.5 billion.

Let's take a closer look at some of the notable changes in the Fund's Q3 2022 and Q4 2022 13F holdings.

Firstly, Armistice Capital put an additional 600,000 shares on the IWM or iShares Trust Russell 2000 ETF. This represented a 23.3% increase, with the value increasing from $593,712 to $732,312. MRTX or Mirati Therapeutics also saw an increase of 158,041 by adding 1,588,000 shares, representing a 19.1% increase, with the value increasing from $132,696 to $158,041.

Armistice Capital also added shares in ExAct Sciences Corp, investing $7.6 million, and Vertex Pharmaceuticals, investing $42.7 million.

The most significant changes can be seen in three holdings. Armistice Capital increased its position in Macrogenics from 6,128,000 to 6,092,000, representing an increase of 92.8%, with the value increased from $21,203 to $40,877. Alkermes also saw a significant decrease from 3,792,000 to 2,900,000, with the value dropping from $84,675 to $75,777, a decrease of 10.5%. The biggest mover, however, was Supernus Pharmaceuticals, which dropped by 4.9%. The value decreased from $155,373 to $155,378.

In conclusion, Armistice Capital saw some impressive gains in the fourth quarter. It added more shares to their top-performing stocks and reduced or eliminated riskier holdings. It is essential to remember that an investor's best interests are not always evident in 13F filings. However, these filings can be a useful tool for investors to understand how institutional investors are shifting their positions in a particular stock. Investors can use this information to make more informed investments based on market trends.